Immune Thrombocytopenia (ITP) is an autoimmune disorder characterized by autoantibody-mediated destruction of platelets. In general, the goal of therapy is the prevention of bleeding complications. Since the risk of life-threatening bleeding complications (eg, intracranial hemorrhage) is extremely rare, the most optimal treatment must remain individualized on the basis of all clinical conditions related to the affected patient. Based on this finding and on our own experiences the majority of affected patients may not require treatment. If indicated, the accepted standard therapies are corticosteroid-base treatments, intravenous immunoglobulins (IVIG) or anti-D, and in severely affected and unresponsive cases, splenectomy.
Romiplostim is a 60 kDa molecule that is composed of four TPO-mimetic peptides that are attached via glycine bridges to an IgG heavy-chain Fc molecule. It effectively competes with eTPO for binding to TPO-receptor, leading to an increase in platelet counts within five to ten days after weekly subcutaneous injection. Romiplostim has been approved for the treatment of ITP in the U.S. and Europe.
The aim of this review is to summarize results the current data from controlled clinical trials on the safety an efficacy of romiplostim in the treatment of ITP.
PDF (574.42 KB PDF FORMAT)
RIS citation (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)
BibTex citation (BIBDESK, LATEX)
My recent paper in Clinical Medicine Insights: Therapeutics was the third I have published in a Libertas Academica journal. Again, I was very pleased by the remarkable speed of publication. It took less than seven weeks from submission of the first manuscript version and two weeks from submission of the revision to the appearance of the final article. When I had unforeseen problems with the transmission of proof corrections because of some software incompatibilities the ...
All authors are surveyed after their articles are published. Authors are asked to rate their experience in a variety of areas, and their responses help us to monitor our performance. Presented here are their responses in some key areas. No 'poor' or 'very poor' responses were received; these are represented in the 'other' category.See Our Results
Copyright © 2013 Libertas Academica Ltd (except open access articles and accompanying metadata and supplementary files.)